Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anthracycline Infusion After Radiotherapy in Pediatric and Young Adult Glioblastoma
NCT06297512Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Nov 2027
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegylated liposomal doxorubicin in glioblastoma (GBM) and diffuse midline glioma (DMG). Primary endpoints: Evaluation prolonged Dox at 1 year, Percentage of Withdrawal from the study rate at 1 year and 3 more. Started Dec 2022; status: recruiting.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
glioblastoma (GBM)diffuse midline glioma (DMG)
Beyond the preview
Go deeper on NCT06297512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297512.